Gynecare TVT Secur for the Management of Stress Urinary Incontinence (SUI)

Stress Urinary Incontinence Clinical Trial

Official title:

Prospective, Non-Randomized, Observational, Multicentre, Study of the TVT Secur in the Surgical Management of Women With Stress Urinary Incontinence

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01029106
• Other study ID #: TVTSecur
• Secondary ID: 047-2009
• Status: Terminated
• Phase: N/A
• First received: October 19, 2009
• Last updated: July 27, 2011
• Start date: September 2009

Study information

• Verified date: July 2011
• Source: Sunnybrook Health Sciences Centre
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Ethics Review Committee
• Study type: Observational

Clinical Trial Summary

This is a prospective, non-randomized, observational, multicentre (5 sites) study in which subjects that have surgically-correctable Stress Urinary Incontinence undergo a TVT SECUR operative procedure.

The study will collect preoperative urologic testing, medical history, and subject quality of life patient questionnaires, Intraoperative procedural data will be collected.

Postoperative complications, urologic, testing, and subject questionnaires will be collected at intervals up to 24 months. The anatomic position of the device will be characterize by transvaginal ultrasound testing.

To determine the rate and/or improvement rate of patients who have received the Gynecare Secur device after 12 months and after 24 months.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 125
• Est. primary completion date: September 2012
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

To be considered eligible to participate in this study, subjects must meet the following requirements:

1. Subject has agreed to undergo surgical implantation of the TVT SECUR System

2. Subject has the complaint of SUI for at least 6 months prior to the Preoperative Evaluation Visit.

3. Subject has confirmed SUI resulting from urethral hypermobility on cough stress testing.

4. Subject has at least 4 gm of urine leakage on 1-hour pad testing during the Preoperative Screening Visit.

5. Subject is at least 18 years of age to maximum of 85 years of age

6. Subject is willing and able to give written informed consent prior to any study related procedures.

7. Subject is willing to return for follow-up evaluation and questionnaire completion at 4-6 weeks, and at 3, 6, 12 and 24 month follow-ups.

8. Subject is willing to undergo transvaginal ultrasound evaluation at the 4 weeks and 12 month follow-up visit.

Exclusion Criteria:

Subjects will not be eligible for entry into the study if they meet one of the following criteria:

1. Subject is pregnant.

2. Subject has had any previous synthetic sub-urethral sling procedure.

3. Subject has current urinary tract or vaginal infections.

4. Subject has blood coagulation disorders.

5. Subject has a compromised immune system or any other conditions that would compromise healing.

6. Subject has upper urinary tract obstruction.

7. Subject is unwilling to provide written informed consent.

8. Subject is unwilling or unable to return for evaluation at 4-6 weeks, and at 3, 6, 12, and 24 months.

9. Subject has uncontrolled detrusor overactivity.

10. Subject has PVR greater than 100 cc.

11. Subject has Peak Flow Rate less than 10 ml/sec.

12. Subject has urethral diverticulum.

13. Subject has significant pelvic organ prolapse (Grade III/IV) requiring surgical treatment.

14. Subject has had radiation therapy to the pelvic area at any time.

15. Subject has current or active history of pelvic cancer.

16. Subject who in the opinion of the investigator is unable and/or unlikely to comprehend the nature, scope and possible consequences of the study and to follow the study procedures and instructions and complete all study related measurements.

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Stress Urinary Incontinence
• Urinary Incontinence
• Urinary Incontinence, Stress

Intervention

Procedure:
• Gynecare TVT Secur
Implant of the Gynecare TVT Secur

Locations

Country	Name	City	State
Canada	Sunnybrook Health Sciences Centre	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
Sunnybrook Health Sciences Centre	Johnson & Johnson

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary endpoints are the cure/improvement rate in the cohort at 12 months.		12 months	No
Secondary	Distribution of percentage of subjects having a decrease of pad weight as compared to baseline		24 months	No
Secondary	Decrease in number of pads used within a 24-hour period as compared to baseline		24 months	No
Secondary	Change in patient questionnaires from baseline		24 months	No
Secondary	Change in the sling position on transvaginal ultrasound		24 months	No
Secondary	Cure/improvement rate at 24 months		24 months	No